检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:郑全玲 李艾黎[1] 戚晓熙[1] 郜雪飞 季晓梅[1]
机构地区:[1]东北农业大学乳品科学教育部重点实验室食品学院.哈尔滨150030
出 处:《中国乳品工业》2014年第3期22-25,38,共5页China Dairy Industry
基 金:乳品科学教育部重点实验室开放基金资助项目(2012KLD-SOF-07)
摘 要:目的:分析和比较嗜酸乳杆菌预防和治疗β-乳球蛋白过敏的作用和效果,为抗过敏性能益生菌的使用提供科学依据。方法:BALB/c小鼠随机分为空白组、β-乳球蛋白过敏组、嗜酸乳杆菌预防组和嗜酸乳杆菌治疗组。建模结束后,采用酶联免疫吸附法(ELISA)检测各组小鼠血清中IgE及Thl/Th2型细胞因子(IL-12、IFN-γ、IL-4)的含量;RT-PCR法检测脾脏中T-bet和GATA-3 mRNA的表达量。结果:嗜酸乳杆菌干预可有效缓解β-乳球蛋白过敏,与过敏组小鼠比较,其血清总IgE和特异性IgE水平明显降低(P<0.05),IFN-γ、IL-12含量及T-bet mRNA表达量显著增加,IL-4含量及GATA-3 mRNA表达显著降低(P<0.05)。特别是嗜酸乳杆菌预防组的抗过敏效果优于治疗组,且预防组调节IFN-γ/IL-4比值(代表Thl/Th2细胞平衡)的能力显著优于治疗组(P<0.05)。结论:嗜酸乳杆菌预防β-乳球蛋白过敏的效果优于其治疗效果。Objective: To analyze and compare the preventative or therapeutic effects of L.acidophilus on the β-lactoglobulin (β-ig) allergy. Methods: The rats were randomly divided into 4 groups: blank group, milk allergy group, Lactobacillus aeidophilus prevention and treatment group. The levels of IgE and Thl/Th2 type cytokine (IL-12, IFN-γ IL-4) in the serum were detected by ELISA. the expressions of T-bet and GATA-3 mRNA in the spleen were measured by quantitative RT-PCR . Results: Compared with the milk allergy group, mice treated with L. acidophilus presented a significant decrease in total IgE and β-lg-specific IgE production as well as lower levels of IL-4 and GATA-3 mRNA expression. In contrast, the serum levels of IFN-γ and IL-12 were significantly increased after oral administration of L.acidophilus (P〈0.05). Especially, when Balb/c mice were orally treated with L.acidophilus before sensitization with/3-1g, the IFN-γ//IL-4 value which represents the Thl/Th2 cell balance was dramatically improved compared with the L.acidophilus treatment group (/}〈0.05) .Conclusion: The anti-allergy effect of L.acidophilus prevention group is better than L.acidophilus treatment group
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15